Blueprint Medicines Publishes Strategy for Advancing Kinase Drug Discovery
"Despite the success of kinase inhibitors in treating cancer, approved drugs focus on less than 5 percent of all kinases and the function of most kinases remains unknown," said Sir
The JCI review article describes how the abnormal activation of kinases drives many hallmarks of tumor biology. Kinases are proven cancer drug targets, but progress in recent years has been largely incremental. In the article,
- Uncovering novel disease drivers and drug targets: New genomics and sequencing approaches are needed to elucidate the biology of the full kinome, which is comprised of 518 kinases, and to uncover the function of kinases of unknown biology (or KUBs) and their potential for drug discovery.
- Crafting highly selective kinase inhibitors: Novel chemical matter and structure-informed design are needed to create more selective and potent therapies that can inhibit new and difficult-to-drug kinase targets. Complete target inhibition with minimal off-target effects is also needed to provide more durable responses with few toxicities, improving outcomes for patients.
- Predicting resistance mutations: Novel approaches in structural biology and computational chemistry are needed to predict future resistance mutations which arise from targeted therapies. Novel chemistry is needed to design a single therapy that can target both the original primary disease driver and the subsequent mutations that cause patients to become refractory to treatment.
- Developing novel combination therapies: Combinations of highly targeted kinase inhibitors acting within a single kinase pathway or between parallel kinase pathways are needed to mount a multi-pronged attack that improves efficacy and delays the onset of treatment resistance.
"We're entering a new era of precision medicine, in which we can craft highly selective kinase inhibitors against previously unaddressed drivers of disease and identify patients who are most likely to respond based on the molecular profile of their cancers," said
About Blueprint Medicines
Forward-Looking Statements
Various statements in this release concerning
CONTACT:
Investor Relations:
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Media Relations:
inVentiv Health PR
212-229-8417
beth.keshishian@inventivhealth.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-publishes-strategy-for-advancing-kinase-drug-discovery-300076250.html
SOURCE